Parallel session abstracts
Ovarian cancer
- Ovarian carcinoma subtypes are different diseases: implications for clinical and translational research
- Targeting cell cycle abnormalities in ovarian cancer using oncolytic adenoviruses
- How to use new pathways to circumvent platinum resistance?
- Proffered paper: A Phase I study of AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor: results in patients with BRCA deficient ovarian cancer (BDOC)
- Proffered paper: Alpha folate receptor (FOLR1) amplification and role in tumour growth independent of folate transport in ovarian cancer (EOC)
- Proffered paper: In vitro and in vivo evaluation of a novel 18F-labeled isatin as an apoptosis PET imaging tracer
